ClinicalTrials.gg
CompletedNCT01121991Updated Aug 7, 2013Results posted

A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies

A Phase 3 interventional study of Recombinant Human-Luteinizing Hormone (Luveris) in Infertility and Ovarian Stimulation, sponsored by EMD Serono. Completed. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing lutropin alfa in Infertility — 1 open to participants now, 1 under way, 1 of them phase 3. lutropin alfa · Infertility.

Enrollment
10th of 11
55 · median 90
Started
2004
the only one that year
Phase 3
3 of 11
1 open now
Registered
5th of 11
by date
Lead sponsor
1 of 11
EMD Serono

Among the 11 studies testing lutropin alfa in Infertility, this one is the 10th largest by enrollment, is the only one that started in 2004, is one of 3 in phase 3, and was the 5th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 11 studies testing lutropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lutropin alfa

lutropin alfa: first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing lutropin alfa in Infertility, or all of them as a file.
02

Study summary

In-vitro fertilization (IVF) of human oocytes followed by the replacement of embryo in the uterine cavity has become a well established treatment for female infertility attributable to damaged fallopian tubes, endometriosis or unexplained causes where alternative forms of therapy have failed. The most commonly used protocols of follicular stimulation now employs follicle stimulating hormone (FSH) and long-acting agonists of gonadotropin releasing hormone (GnRH) to prevent the occurrence of a mid-cycle luteinizing hormone (LH) surge and to ensure the induction of well-synchronized larger cohort of ovarian follicles.

The results of a number of studies have demonstrated that in the majority of clinical situations, FSH administration alone is sufficient to achieve successful follicular development. A study had shown that in subjects receiving recombinant human-follicle stimulating hormone (r-hFSH) and recombinant human-luteinizing hormone (r-hLH), pregnancy rates were similar in the younger and older age groups, however, in women receiving r-hFSH alone, there was a significant decline in pregnancy rates for women 35 and older. This particular study also went on to show that the subgroup of women 35 and older, may benefit from supplementary r-hLH. A number of studies have been conducted to assess the safety and efficacy of r-hLH administered concomitantly with r-hFSH in the presence of developing follicles to reduce the rate of growth of intermediate and small follicles while allowing the dominant follicle to continue to progress.

This was a Phase III, open-label, multicentre study to evaluate safety and efficacy of addition of Recombinant Human-Luteinizing Hormone (Luveris) to a standard assisted reproductive technologies (ART) protocol.

Read the detailed description

Luteinizing hormone is a heterodimeric glycoprotein composed of a non-covalent association of an α and a β subunit. Prior to the generation of human-LH (hLH) through recombinant technology, hLH had only been available for therapeutic use as human menopausal gonadotropins (hMG), a co-extracted, purified preparation of hLH and hFSH from urine of post menopausal women. Recombinant Human-Luteinizing Hormone (Luveris) has been found to be well tolerated in human pharmacokinetic and pharmacodynamic studies at doses of up to 40,000 IU in healthy female volunteers without any Serious Adverse Event (SAE) experience being reported.

OBJECTIVES

  • To evaluate safety and efficacy of addition of Recombinant Human-Luteinizing Hormone (Luveris) to a standard ART procedure.

In this study, subjects were first treated with a GnRH agonist to induce pituitary desensitization according to centre's standard practice followed by administration of r-hFSH. All subjects were then treated with Recombinant Human -Luteinizing Hormone (Luveris)150 IU per day subcutaneous (s.c.) from Day 6 of stimulation of their ART treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose.

03

Conditions studied

  • Infertility
  • Ovarian Stimulation

Browse trials for

Keywords

  • Infertility
  • Ovarian Stimulation
  • Luveris
  • Lutropin alpha
  • Controlled ovarian stimulation
  • Reproductive techniques, assisted
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects who underwent ovarian stimulation for ART (IVF/ICSI) using r-hFSH.
  • Subjects who in the opinion of the treating investigator met any of the following criteria to require r-LH supplementation during the ovarian stimulation:

    • were selected for a GnRH agonist protocol to induce pituitary desensitization
    • previous poor ovarian response to r-hFSH alone
    • aged 35 to 40 years
    • elevated baseline hormone parameters that were predictive of poor ovarian response
  • Female subjects aged between 18-40 years
  • Subjects with uterine cavity able to sustain embryo implantation or pregnancy
  • Subject who had no known infection with , or C virus
  • Subjects who were willing to participate and comply with the protocol for the duration of the study
  • Subjects who had given , prior to any study-related procedure not part of normal medical care

Exclusion criteria

Exclusion Criteria:

  • Subjects with systemic disease (e.g. insulin-dependent diabetes, epilepsy, severe migraine, intermittent porphyria, hepatic, renal or cardiovascular disease, severe -dependent asthma)
  • Any to being pregnant and/or carrying a pregnancy to term
  • Subjects with abnormal gynecological bleeding of undetermined origin
  • Subjects with known allergy to gonadotrophin preparations
  • Subjects with any medical condition for which the use of gonadotrophin preparations was contraindicated
  • Subjects who had previously entered into this study or simultaneously participated in another clinical drug trial
  • Subjects with any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years
  • Subjects who had refused or were unable to comply with protocol
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)

    Mean number of metaphase II oocytes was calculated for each participant undergoing ovum pick up for ICSI. ICSI is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.

    Time frame: On the day of ovum pick up (Day 1 or 2 after human chorionic gonadotropin [hCG] administration).

  2. Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)

    Mean number of oocytes undergoing ovum pick up for IVF were calculated for each participant. IVF is a process by which egg cells are fertilized by sperm outside the body, in-vitro.

    Time frame: On the day of ovum pick up (Day 1 or 2 after hCG administration).

Secondary outcomes

  1. Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up

    Mean number of oocytes retrieved per number of follicles aspirated on the day of ovum pick up was calculated. Oocyte retrieval is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

    Time frame: On day of ovum pick up (Day 1 or 2 after hCG administration)

  2. Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies

    Biochemical pregnancy: A positive pregnancy test defined as hCG level \>10 IU/L in a sample taken at least 14 days after Day 3 embryo transfer or 12 days after Day 5/6 embryo transfer with no further ultrasound confirmation of the existence of a gestational sac in the uterus. Clinical pregnancy: Existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.

    Time frame: Post-hCG days 15-20 and post-hCG days 35-42.

  3. Number of Participants With Multiple Pregnancies

    Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.

    Time frame: Post-hCG Day 35-42.

  4. Number of Live Births

    A live birth occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact.

    Time frame: Post-hCG days 15-20 to pregnancy follow up.

  5. Pregnancy Loss Per Clinical Pregnancy

    Preclinical miscarriage: Spontaneous cessation of a biochemical pregnancy. Early spontaneous abortion: Any spontaneous abortion occurring after confirmation of clinical pregnancy and before completion of 12 weeks of gestation. Late spontaneous abortion: any spontaneous abortion occurring between completion of 12 weeks of gestation and prior to a viable stage. Pregnancy loss per clinical pregnancy was measured as a percentage.

    Time frame: Post-hCG days 35-42.

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation.

    AEs: Any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. TEAEs: AEs that occur during treatment with the study drug. It also included incidences of mild, moderate and severe ovarian hyperstimulation syndrome (OHSS). SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.

    Time frame: From stimulation Day 1 (S1) to post-hCG days 35-42 (safety visit).

07

Results

Posted Mar 18, 2011

Participant flow

Participants were recruited in 4 study centers in Canada from September 2004 to October 2005.

Participant flow — Overall Study
MilestoneRecombinant Human-Luteinizing Hormone (Luveris)
Started52
Completed46
Not completed6
Withdrew: Lack of ovarian response2
Withdrew: No oocytes retrieved3
Withdrew: No fertilization1

Outcome measures

PrimaryMean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)

Mean number of metaphase II oocytes was calculated for each participant undergoing ovum pick up for ICSI. ICSI is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.

Time frame:
On the day of ovum pick up (Day 1 or 2 after human chorionic gonadotropin [hCG] administration).
Reported as:
Mean · Metaphase II Oocytes
Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)
Metaphase II OocytesRecombinant Human-Luteinizing Hormone (Luveris)
Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)9.5 ± 4.2
PrimaryMean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)

Mean number of oocytes undergoing ovum pick up for IVF were calculated for each participant. IVF is a process by which egg cells are fertilized by sperm outside the body, in-vitro.

Time frame:
On the day of ovum pick up (Day 1 or 2 after hCG administration).
Reported as:
Mean · oocytes
Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)
oocytesRecombinant Human-Luteinizing Hormone (Luveris)
Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)7.5 ± 6.8
SecondaryMean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up

Mean number of oocytes retrieved per number of follicles aspirated on the day of ovum pick up was calculated. Oocyte retrieval is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

Time frame:
On day of ovum pick up (Day 1 or 2 after hCG administration)
Reported as:
Mean · oocytes per aspirated follicle
Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up
oocytes per aspirated follicleRecombinant Human-Luteinizing Hormone (Luveris)
Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up0.9 ± 0.2
SecondaryNumber of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies

Biochemical pregnancy: A positive pregnancy test defined as hCG level \>10 IU/L in a sample taken at least 14 days after Day 3 embryo transfer or 12 days after Day 5/6 embryo transfer with no further ultrasound confirmation of the existence of a gestational sac in the uterus. Clinical pregnancy: Existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.

Time frame:
Post-hCG days 15-20 and post-hCG days 35-42.
Reported as:
Number · participants
Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies
participantsRecombinant Human-Luteinizing Hormone (Luveris)
Participants with confirmed biochemical pregnancy22
Participants with confirmed clinical pregnancy14
SecondaryNumber of Participants With Multiple Pregnancies

Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.

Time frame:
Post-hCG Day 35-42.
Reported as:
Number · participants
Number of Participants With Multiple Pregnancies
participantsRecombinant Human-Luteinizing Hormone (Luveris)
Number of Participants With Multiple Pregnancies4
SecondaryNumber of Live Births

A live birth occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact.

Time frame:
Post-hCG days 15-20 to pregnancy follow up.
Reported as:
Number · Live births
Number of Live Births
Live birthsRecombinant Human-Luteinizing Hormone (Luveris)
Number of Live Births13
SecondaryPregnancy Loss Per Clinical Pregnancy

Preclinical miscarriage: Spontaneous cessation of a biochemical pregnancy. Early spontaneous abortion: Any spontaneous abortion occurring after confirmation of clinical pregnancy and before completion of 12 weeks of gestation. Late spontaneous abortion: any spontaneous abortion occurring between completion of 12 weeks of gestation and prior to a viable stage. Pregnancy loss per clinical pregnancy was measured as a percentage.

Time frame:
Post-hCG days 35-42.
Reported as:
Number · Percentage of pregnancy loss
Pregnancy Loss Per Clinical Pregnancy
Percentage of pregnancy lossRecombinant Human-Luteinizing Hormone (Luveris)
Pregnancy Loss Per Clinical Pregnancy7.14
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation.

AEs: Any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. TEAEs: AEs that occur during treatment with the study drug. It also included incidences of mild, moderate and severe ovarian hyperstimulation syndrome (OHSS). SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.

Time frame:
From stimulation Day 1 (S1) to post-hCG days 35-42 (safety visit).
Reported as:
Number · Number of participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation.
Number of participantsRecombinant Human-Luteinizing Hormone (Luveris)
TEAEs15
SAEs3
Discontinuation due to AEs0

Adverse events

Collected over AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 35-42 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recombinant Human-Luteinizing Hormone (Luveris)—3/52 (5.8%)15/52 (28.8%)
Most frequent serious events
Most frequent serious events
EventRecombinant Human-Luteinizing Hormone (Luveris)
Abdominal painGastrointestinal disorders1/52
MetrorrhagiaReproductive system and breast disorders1/52
Post procedural hemorrhageInjury, poisoning and procedural complications1/52
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRecombinant Human-Luteinizing Hormone (Luveris)
Local tolerability of injectionsGeneral disorders5/52
Ovarian Hyperstimulation SyndromeReproductive system and breast disorders3/52
ConstipationGastrointestinal disorders2/52
DiarrheaGastrointestinal disorders2/52
FatigueGeneral disorders2/52
Procedural painInjury, poisoning and procedural complications2/52
Abdominal distensionGastrointestinal disorders1/52
FlatulenceGastrointestinal disorders1/52
Injection site painGeneral disorders1/52
Vulvovaginal mycotic infectionInfections and infestations1/52

Baseline characteristics

Age Continuous
Age Continuous(years)Recombinant Human-Luteinizing Hormone (Luveris)
Mean34.6 ± 3.6
Age, Customized
Age, Customized(participants)Recombinant Human-Luteinizing Hormone (Luveris)
<35 years22
>=35 years30
Sex: Female, Male
Sex: Female, Male(Participants)Recombinant Human-Luteinizing Hormone (Luveris)
Female52
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Recombinant Human-Luteinizing Hormone (Luveris)
Asian3
White47
Hispanic1
Aboriginal1
Region of Enrollment
Region of Enrollment(participants)Recombinant Human-Luteinizing Hormone (Luveris)
Canada52
Smoking
Smoking(participants)Recombinant Human-Luteinizing Hormone (Luveris)
0 cigarettes per day50
6-20 cigarettes per day1
>20 cigarettes per day1
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a primary completion of Sep 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2010
First posted
May 12, 2010
Start
Sep 2004
Primary completionActual
Sep 2005
Results first posted
Mar 18, 2011
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01121991
Lead sponsor
EMD Serono
First posted
May 12, 2010
Start date
Sep 2004
Primary completion
Sep 2005
Results posted
Mar 18, 2011
Last update
Aug 7, 2013

Study contacts

Medical Responsible
study director · EMD Serono Canada Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutropin alfa

Start the discussion